

Prevalence of Hepatitis C Virus in Thalassemia and Hemoglobinopathies in Duhok City/Iraq

¹Arwa Abass Al-Khaffajy and ²Abdulrhem Thonnon Younis Al-Ghazal

¹Department of Medical Organisms, College of Medicine, University of Nenaveh, Mosul, Iraq

²Department of Biology, College of Science, University of Mosul, Mosul, Iraq

Abstract: Hepatitis C virus regards as one of the most important challenges in present era because of its increasing infection all over the world. Infection with HCV causes severe complications end up with shortage in liver functions, cancer and death. The aim of this study is to determine the rate of HCV antibodies prevalence in thalassemia patients and other hemoglobinopathies in Duhok City, Iraq. About 190 blood samples were collected at December 2015-August 2016 from Thalassemia Unit in Golan Hospital, Aqra, Duhok, Iraq. Chemical immunofluorescence technique was used to detect the antibodies and antigens for HCV. The positive samples were retested as additional confirmation to the results. The results revealed that the total rate of HCV prevalence reached 15.26% (29 from 190) but in patients with thalassemia the ratio was 11.05% (21 from 117). For age groups, the highest rate of infection (65.5%) was in patients with age ranged between 11-20 years. The result revealed that HCV infects 69% of patients with thalassemia major. There are no relationship between HCV infection and each of sex, blood groups and Rh factor.

Key words: HCV, thalassemia, hemoglobinopathies, Rh factor, antibody, cancer

INTRODUCTION

Thalassemia is an inherited blood disorder that affects the body's ability to produce hemoglobin and red blood cell. Thalassemia types are alpha thalassemia and β thalassemia. β thalassemia includes β Thalassemia Major (β TM) which regards the most prevalence disease over all the world (200 million patients) (Li, 2017). In Iraq the prevalence ratio may reach 5% (Hassan *et al.*, 2003). In some societies practice the habit of consanguineous marriage the ratio may increase (Samavat and Modell, 2004). This disease characterized with distortion of globin chains which lead to malfunction in hemoglobin end up with destruction of red blood cells in bone marrow and causes death if it is not treated (Rund and Rachmilewitz, 2005). In 2013 about 25000 patients dead by thalassemia (Li, 2017). Patients with β TM need blood transfusions 1-2 time monthly to keep them alive (Rund and Rachmilewitz, 2005). The blood transfusions may cause blood born infections such as Hepatitis C Virus infection (HCV). HCV is the most transmitted virus through the blood (Rich and Taylor, 2010). This virus recorded in 1989 (Houghton, 2009) belong to Flaviviridae family with RNA genome (Smith *et al.*, 2014). The global number of patients with chronic HCV may exceeds one billion with 750000 annual deaths (Thomas, 2013). The infection with HCV causes

acute infection may reach for 6 months without symptoms (Tarky *et al.*, 2013), 80% of them may change to chronic infection without symptoms, thus, HCV is also named the silent disease which end up within 10-20 years to liver fibrosis or cirrhosis (Lee *et al.*, 2015). HCV has long incubation period and late seroconversion which causes difficulties in sero-diagnosis especially in new infected patients. Therefore, the early diagnosis of viral nucleic acid and serological tests using chemiluminescence technique (Snibe® Systems) are very important to detect the low level of viral RNA during incubation period (Mattsson *et al.*, 1992; Lai *et al.*, 1993; Guo *et al.*, 2012). The aim of this study is to determine the prevalence rate of HCV in patients with thalassemia and other hemoglobinopathies in Aqra, Duhok City, Iraq.

MATERIALS AND METHODS

Blood sample: About 190 blood samples were collected from patients with thalassemia and hemoglobinopathies (β TM, sickle β -thalassemia and sickle cell anemia, β thalassemia intermedia and alpha thalassemia) in Golan Hospital, Aqra, Duhok, Iraq from December 2015-August 2016. Age patients ranged between 1-46 years. Blood samples (6-7 mL) were taken and put in serum-separating tube (contains special gel).

The sample centrifuged, incubated (37°C) for 5 min, centrifuged for 10 min at 1000 rpm. Within 3 h serology test performed using Snibe Diagnostic systems and Maglumi 1000® (Chemiluminescence Immunoassay (CLIA) Technology)) which give 100% sensitivity and 99.93% specificity (Guo *et al.*, 2012). Anti-Hepatitis C IgG antibodies test was used as standard test according to, recommendation from Centers for Disease Control and prevention (CDC). Results interpreted as non-reactive (negative) if it is <20 AU/mL or reactive if it is equal or more than 20 AU/mL (positive).

RESULTS AND DISCUSSION

Total prevalence of HCV was 15.26% (n = 19) whereas prevalence of HCV in thalassemia patients was 11.05% (n = 19) (Table 1). The results showed that HCV infect 58.6% (n = 17) of male compared with 41.4% (n = 12) in female (Table 2).

The age of patients ranged between 1-46 years, patients with age ranged between 11-20 infected with 65.5% (n = 19) from the total HCV infected patients (n = 29). Group with 21-30 years infected with 24%, group with 1-10 years was infected with 6.8%, group with 31-40 years infected with 3.4% (Table 3).

HCV infections varies according to the types of hemoglobinopathies. HCV infections in patients with β TM reached 69% (n = 20) whereas HCV infections in patients with sickle cell anemia was 17.2% (n = 5). In

patients with sickle beta thalassemia, HCV infects 10.3% of them whereas in patients with beta thalassemia minor infection ratio with HCV reached 3.4% (Table 4).

HCV infects 44.8%, 31%, 20.7% and 3.4% of patients with O+, A+, B+ and AB+ blood groups, respectively (Table 5). All patients with HCV were positive for rhesus factor (Table 6).

Patients with thalassemia and hemoglobinopathies need frequent blood transfusions which are important for their improvement of survival and reduce dangerous complications that produced from severe anemia. On the other hand this frequent blood transfusions will increase the probability of infection with different microbes especially HCV, HBV and HIV (Rund and Rachmilewitz, 2005). Previous study (2005-2006) national survey (general population) performed through all provinces in Iraq and recorded low prevalence of HCV (0.4%) (Tarky *et al.*, 2013). In present study prevalence ratio of HCV was 15.06% from 190 patients suffer from hemoglobinopathies whereas in thalassemia patients (beta major and beta intermedia) HCV prevalence was 11.05%. This result was lower than other study (17%) performed on 200 thalassemia patients in Mosul City (Khalid and Abdullah, 2012). In other Iraqi cities including Diyala (Raham *et al.*, 2011) and Karbala (Al-Greti, 2013) higher ratio recorded 26.4% and 37%, respectively whereas in Babylon City lower prevalence was recorded (7.5%) (Tarish and Shakeer, 2014). These variations in prevalence of HCV may belong to variations in hygienic surveillance especially tests blood. In addition, it reflect the variation of health awareness of the citizens in these cities. In Baghdad the prevalence ratio of HCV in thalassemia patients increased up to 67% in 1989 (Al-Kubaisy *et al.*, 2006) then reduced to 46% in 2008 (Abed, 2010).

Table 1: Prevalence of HCV in Agra, Duhok, Iraq

HCV	Number	Percentage
Negative	161	84.74
Positive	29	15.26
Total	190	100.00

Table 2: Prevalence of HCV in male and female

Sex	Number	Percentage	-Ve HCV	+Ve HCV	Statically values	Significance
Male	87	45.8	70 (43.5%)	17 (58.6%)	2.270	0.096
Female	103	54.2	91 (55.5%)	12 (41.4%)		
Total	109	100	161 (100%)	29 (100%)		

Table 3: Prevalence of HCV in age groups

Age groups	Anemia patients	-Ve HCV	+Ve HCV	Statically values	Significance
1-10	91	89 (55.3%)	2 (2.19%)	28.21	0.0001
11-20	57	38 (23.6%)	19 (33.3%)		
21-30	32	25 (15.5%)	7 (21.8%)		
31-40	6	5 (3.1%)	1 (16.6%)		
41-50	4	4 (2.5%)	-		
Total	190	161	29		

Table 4: Prevalence of HCV according to the type of thalassemia and hemoglobinopathies

Anemia type	Number (%)	-Ve HCV	+Ve HCV	Statically values	Freedom degree	Significance
β TM	85 (44.7)	65 (40.4%)	20 (69.0%)	10.235	4	0.037
Sickle cell anemia	32 (16.8)	27 (16.8%)	5 (17.2%)			
Beta thalassemia anemia	41 (21.6)	38 (23.6%)	3 (10.3%)			
Beta thalassemia intermedia	23 (12.1)	22 (13.7%)	1 (3.4%)			
Alpha thalassemia	9 (4.7)	9 (5.6%)	-			
Total	190(100)	161(100%)	29(100%)			

Table 5: Prevalence of HCV according to blood groups

Blood group	Number	-Ve HCV	+Ve HCV	Statically values	Freedom degree	Significance
O+	69 (36.3%)	56 (34.8%)	13 (44.8%)	4.224	7	0.75
A+	56 (29.5%)	47 (29.2%)	9 (31.0%)			
B+	36 (18.9%)	30 (18.6%)	6 (20.7%)			
AB+	13 (6.8%)	12 (7.5%)	1 (3.4%)			
A-	7 (3.7%)	7 (4.3%)	-			
O-	4 (2.1%)	4 (2.5%)	-			
B-	3 (1.6%)	3 (1.9%)	-			
AB-	2 (1.1%)	2 (1.2%)	-			
Total	190 (100%)	161 (100%)	29 (100%)			

Table 6: Prevalence of HCV in patients with positive rhesus factor

Rhesus factor type	-Ve HCV	+Ve HCV	Statically values	Freedom degree	Significance
Positive	145 (90.1%)	29 (100.0%)	3.147	1	0.06
Negative	16 (9.9%)	-			

and in 2011 it become 16.9% (Albahadle *et al.*, 2013) and this gradual decreasing may be belong to improvement in check procedures for blood donors in last years. In neighboring countries like Iran, the ratio of HCV prevalence in South West Iran was 28.1% (Boroujerdnia *et al.*, 2009) whereas in North Iran it reduced to 13.6% (Jafroodi *et al.*, 2015) then reduced to 8% in Esfahan City (Ataei *et al.*, 2012). In Pakistan other studies recorded high ratio (49%) of HCV prevalence in thalassemia patients (Din *et al.*, 2014) and increased in another study to reach 56% (Saeed *et al.*, 2015). In other countries such as Hong Kong the ratio reached 46.8% (Lau *et al.*, 1993), Brazil 46.8% (Covas *et al.*, 1993), India 43.6% (Choudhury *et al.*, 1998), Burma (Myanmar) 55.6% (Okada *et al.*, 2000), Malaysia 22.4% (Jamal *et al.*, 1998), Taiwan 17% (Chung *et al.*, 1997). These variations are very clear and may belong to different reasons such as sample size, type of technique (ELISA, Minividas, Immunofluorescences, Chemiluminescence), variations in kit types and their trade mark, time of incubation during the test and the differences in blood test procedures between countries, cities and societies. In addition, to that the variations in customs and social customs in each society such as tattoo, body piercing, take drugs by injection. Level of hygienic surveillance in addition to hygienic awareness of people may interpret all these variation in results.

HCV characterized with low viral load, long incubation period which may extended to 6 months and asymptomatic in acute and chronic periods, all these reasons will delay the seroconversion and finally, delay diagnosis of HCV in blood donor leading to increase the probability of infections to patients with thalassemia and hemoglobinopathies through hemolysis and this interprets the increasing of infection in thalassemia patients in all previous studies. To reduce the infection with HCV, many countries insert the DNA test within the routine protocol test which recognize very low concentration of viral DNA and RNA (Dodd *et al.*, 2002; Whittaker *et al.*, 2008).

This study revealed that HCV infect males (8.95%) more than females (6.4%), this result coincided with other studies performed inside and outside Iraq (Raham *et al.*, 2011; Abed, 2010; Boroujerdnia *et al.*, 2009; Jafroodi *et al.*, 2015; Satia *et al.*, 2016; Namat Allah, 2013; Al-Juboury *et al.*, 2010). The present study showed that the age group with 11-20 years infected with the highest ratio (27%) compared with other groups and these results agreed with other studies Albahadle *et al.*, 2013; Boroujerdnia *et al.*, 2009; Satia *et al.*, 2016). The highest ratio of infection with HCV was in the group with 10-20 years which may be attributed to more frequent number of blood transfusions in older patients compared with very low number of blood transfusions in group with 1-10 years and this result was confirmed with other studies (Albahadle *et al.*, 2013; Boroujerdnia *et al.*, 2009).

Our results revealed that HCV infects patients with β TM with high ratio (69%) compared with other hemoglobinopathies. These results agreed with previous study showed that HCV infects patients with β TM (21%) compared with 12.9% beta thalassemia intermedia (Mirmomen *et al.*, 2006). These differences in HCV infections may be attributed to more frequent hemodialysis in β TM whom suffer from high shortage of Hb, so, they need more frequent blood transfusions compared with beta thalassemia intermedia (have simple shortage in Hb). There is no significant relationship between HCV infections and blood groups A+, B+, O+ and Rh. These results come in agreement with other studies (Mohammadali and Pourfathollah, 2014; Jeremiah *et al.*, 2008; Gao *et al.*, 2011).

CONCLUSION

The prevalence ratio of HCV infections in thalassemia patients is lower than other studies in or out Iraq. The most prevalence of HCV was in β TM patients compared with other types. Approval of chemical immunofluorescence technique and viral nucleic acid test

as routine tests before blood transfusion are very important to reduce HCV prevalence in patients with thalassemia and hemoglobinopathies.

REFERENCES

- Abed, B.A., 2010. Prevalence of Hepatitis C Virus (HCV) among Thalassemipatients in Ibn-Albalady Hospital. *J. AlNahrain Univ. Sci.*, 13: 121-126.
- Al-Greti, S.H.H., 2013. Prevalence of Hepatitis C virus in Beta-Thalassemia major patients at Karbala overnorate. *J. Univ. Babylon*, 21: 2801-2805.
- Al-Juboury, A.W., M.K. AL-ASSADI and A.M. Ali, 2010. Seroprevalence of Hepatitis B and C among blood donors in Babylon Governorate-Iraq. *Med. J. Babylon*, 7: 121-129.
- Al-Kubaisy, W.A., K.T. Al-Naib and M. Habib, 2006. Seroprevalence of hepatitis C virus specific antibodies among Iraqi children with thalassaemia. *Eastern Mediterranean Health J.*, 12: 204-210.
- Albahadle, A.K.J., A.A. Abass and A.H. Ali, 2013. Prevalence of hepatitis c infection among multitransfused Thalassemia major patients in Ibn-Albalady center of Thalassemia. *AlQadisiyah Med. J.*, 9: 73-84.
- Ataei, B., M. Hashemipour, N. Kassaian, R. Hassannejad and Z. Nokhodian *et al.*, 2012. Prevalence of anti HCV infection in patients with Beta-thalassemia in Isfahan-Iran. *Intl. J. Preventive Med.*, 3: S118-S123.
- Boroujerdnia, M.G., M.A.A. Zadegan, K.M. Zandian and M.H. Rodan, 2009. Prevalence of Hepatitis-C Virus (HCV) among Thalassemia patients in Khuzestan Province, Southwest Iran. *Pak. J. Med. Sci.*, 25: 113-117.
- Choudhury, N., S. Saraswat and M. Naveed, 1998. Serological monitoring of Thalassaemia major patients for transfusion associated viral infections. *Indian J. Med. Res.*, 107: 263-268.
- Chung J.L., J.K. Kao, M.S. Kong, C.P. Yang and I.J. Hung *et al.*, 1997. Hepatitis C virus infection in polytransfused children. *Eur. J. Pediatr.*, 156: 546-549.
- Covas D.T., N.E. Boturao and M.A. Zago, 1993. The frequency of blood-born viral infections in a population of multitrans fused Brazilian patients. *J. Sao Paulo Instit. Trop. Med.*, 35: 271-273.
- Din, G., S. Malik, I. Ali, S. Ahmed and J.I. Dasti, 2014. Prevalence of Hepatitis C virus infection among Thalassemia patients: A perspective from a multi-ethnic population of Pakistan. *Asian Pac. J. Trop. Med.*, 7: S127-S133.0
- Dodd, R.Y., E.P. Notari and S.L. Stramer, 2002. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. *Transfusion*, 42: 975-979.
- Gao, X., Q. Cui, X. Shi, J. Su and Z. Peng *et al.*, 2011. Prevalence and trend of Hepatitis C virus infection among blood donors in Chinese mainland: A systematic review and meta-analysis. *BMC. Infect. Dis.*, 11: 1-14.
- Guo, J.X., J. Xu, L. Chen, J. Liu and J. Zhao *et al.*, 2012. Comparison of two different methods to detect HIV antibodies. *Chinese J. Exp. Clin. Virol.*, 26: 492-493.
- Hassan, M.K., J.Y. Taha, L.M. Al-Naama, N.M. Widad and S.N. Jasim, 2003. Frequency of haemoglobinopathies and glucose-6-phosphate dehydrogenase deficiency in Basra. *Eastern Mediterranean Health J.*, 9: 45-54.
- Houghton, M., 2009. Discovery of the Hepatitis C virus. *Liver Intl.*, 29: 82-88.
- Jafroodi, M., A. Davoudi-Kiakalayeh, Z. Mohtasham-Amiri, A.A. Pourfathollah and A. Haghbin, 2015. Trend in prevalence of Hepatitis C virus infection among β -Thalassemia major patients: 10 years of experience in Iran. *Intl. J. Preventive Med.*, 6: 1-5.
- Jamal, R., G. Fadzillah, S.Z. Zulkifli and M. Yasmin, 1998. Seroprevalence of hepatitis B, hepatitis C, CMV and HIV in multiply transfused thalassemia patients: Results from a thalassemia day care center in Malaysia. *Southeast Asian J. Trop. Med. Public Health*, 29: 792-794.
- Jeremiah, Z.A., B. Koate, F. Buseri and F. Emelike, 2008. Prevalence of antibodies to Hepatitis C virus in apparently healthy Port Harcourt blood donors and association with blood groups and other risk indicators. *Blood Trans.*, 6: 150-155.
- Khalid, M.D. and B.A. Abdullah, 2012. Prevalence of anti-HCV antibodies among Thalassemia patients in Mosul City, Iraq. *J. Life Sci.*, 6: 489-491.
- Lai, M.E., S.V. De, F. Argioli, P. Farci and A.P. Mazzoleni *et al.*, 1993. Evaluation of antibodies to Hepatitis C virus in a long-term prospective study of Posttransfusion Hepatitis among Thalassemic children: Comparison between first-and second-generation assay. *J. Pediatr. Gastroenterol. Nutr.*, 16: 458-464.
- Lau, Y.L., C.B. Chow, A.C. Lee, K.W. Ng and W.L. Lim *et al.*, 1993. Hepatitis C virus antibody in multiply transfused Chinese with Thalassaemia major. *Bone Marrow Trans.*, 12: 26-28.

- Lee, J., J. Conniff, C. Kraus and S. Schrager, 2015. A brief clinical update on Hepatitis C--the essentials. *WMJ. Off. Pub. State Med. Soc. Wisconsin*, 114: 263-269.
- Li, C.K., 2017. New trend in the epidemiology of Thalassaemia. *Best Pract. Res. Clin. Obstetrics Gynaecol.*, 39: 16-26.
- Mattsson, L., L. Grillner and O. Weiland, 1992. Seroconversion to Hepatitis C virus antibodies in patients with acute posttransfusion non-A, non-B hepatitis in Sweden with a second generation test. *Scand. J. Infect. Dis.*, 24: 15-20.
- Mirmomen, S., S.M. Alavian, B. Hajarizadeh, J. Kafaee and B. Yektaparast *et al.*, 2006. Epidemiology of hepatitis B, hepatitis C and human immunodeficiency virus infections in patients with beta-thalassemia in Iran: A multicenter study. *Arch. Iran Med.*, 9: 319-323.
- Mohammadali, F. and A. Pourfathollah, 2014. Association of ABO and Rh blood groups to blood-borne infections among blood donors in Tehran-Iran. *Iran. J. Pub. Health*, 43: 981-989.
- Namat Allah H.L., 2013. Seroprevalence of Hepatitis C virus and Hepatitis G virus in Kirkuk City patients and their effect on various factors. Masters Thesis, University of Tikrit, Tikrit, Iraq.
- Okada, S., K. Taketa, T. Ishikawa, T. Koji and T. Swe *et al.*, 2000. High prevalence of Hepatitis C in patients with Thalassemia and patients with liver diseases in Myanmar (Burma). *Acta Med. Okayama*, 54: 137-138.
- Raham, T.F., S.S.A. Wahed and H.N. Alhaddad, 2011. Prevalence of hepatitis c among patients with β thalasemia in Diyala-Iraq. *AlTaqani*, 24: 113-120.
- Rich, J.D. and L.E. Taylor, 2010. The beginning of a new era in understanding Hepatitis C virus prevention. *J. Infect. Dis.*, 202: 981-983.
- Rund, D. and E. Rachmilewitz, 2005. β -Thalassemia. *New Engl. J. Med.*, 353: 1135-1146.
- Saeed, U., Y. Waheed, M. Ashraf, U. Waheed and S. Anjum *et al.*, 2015. Estimation of Hepatitis B virus, Hepatitis C virus and different clinical parameters in the Thalassemic population of capital twin cities of Pakistan. *Virol. Res. Treat.*, 6: 11-16.
- Samavat, A. and B. Modell, 2004. Iranian national thalassaemia screening programme. *BMJ.*, 329: 1134-1137.
- Satia, S., M. Jais and M. Debbarma, 2016. Seroprevalence of Hepatitis B and Hepatitis C among Thalassemia patients at a Tertiary Care Hospital in North India. *Eur. J. Pharm. Med. Res.*, 3: 608-611.
- Smith, D.B., J. Bukh, C. Kuiken, A.S. Muerhoff and C.M. Rice *et al.*, 2014. Expanded classification of Hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. *Hepatology*, 59: 318-327.
- Tarish, A.H. and W.H. Shakeer, 2014. Hepatitis C infection among children with Beta-Thalassemia major in Babylon center of hereditary blood disorders. *Kerbala J. Med.*, 7: 1945-1951.
- Tarky, A.M., W. Akram, A.S. Al-Naaimi and A.R. Omer, 2013. Epidemiology of viral Hepatitis B and C in Iraq: A national survey 2005-2006. *Zanco J. Med. Sci.*, 17: 370-380.
- Thomas, D.L., 2013. Global control of Hepatitis C: Where challenge meets opportunity. *Nat. Med.*, 19: 850-858.
- Whittaker, S., N. Carter, E. Arnold, N. Shehata and K.E. Webert *et al.*, 2008. Understanding the meaning of permanent deferral for blood donors. *Trans.*, 48: 64-72.